Country: Philippines
Language: English
Source: FDA (Food And Drug Administration)
Candesartan Cilexetil
N/A; Importer: Celltrion Healthcare Philippines, Inc.; Distributor: N/A
Candesartan Cilexetil
16 mg
Tablet
Alu/PVC/PVDC Blister pack x 7's (Box of 7's and 28's), PP/Alu Blister Pack x 7's (Box of 7's and 28's), Blister Pack x 7's; (Box
Delpharm Novara S.R.L., Italy
2023-10-19
CANDESARTAN cilexetil BLOPRESS ® 8MG TABLET 16MG TABLET ANGIOTENSIN II RECEPTOR ANTAGONIST FORMULATION Candesartan cilexetil (Blopress) tablets (8mg, 16mg) Each tablet contains 8mg or 16mg candesartan cilexetil. INDICATIONS Hypertension Treatment of patients with heart failure and impaired left ventricle systolic function. DOSAGE AND ADMINISTRATION Usual adult dose is 8 or 16mg, orally administered once daily and could be adjusted by the physician according to patient’s condition. For heart failure, up-titration to target dose of 32mg once daily. Candesartan cilexetil (Blopress) tablet may be administered with other antihypertensive agents. Candesartan cilexetil (Blopress) tablet may be administered with or without food. In elderly patients and patients with impaired renal and hepatic functions, a lower dose should be considered and adjust according to response. Due to limited experience, not recommended in very severe/end-stage renal impairment. CONTRAINDICATIONS Candesartan cilexetil (Blopress) Tablet is contraindicated in the following patients – (1) Patients with a history of hypersensitivity to any of the ingredients of this drug. (2) Pregnant women or women having possibilities of being pregnant. (3) Patients with diabetes on aliskerin fumarate (excluding patients with significantly uncontrolled blood pressure despite treatment with other antihypertensive therapy) [Increased risks of non-fatal stroke, renal dysfunction, hyperkalemia or hypotension has been reported]. (See Important Precautions.) PRECAUTIONS 1. CAREFUL ADMINISTRATION (CANDESARTAN CILEXETIL (BLOPRESS) TABLET SHOULD BE ADMINISTERED WITH CARE IN THE FOLLOWING PATIENTS). (1) Patients with a history of drug hypersensitivity. (2) Patients with hepatic dysfunction Hepatic dysfunction may be aggravated. Since a decrease in the clearance of the active metabolite candesartan is predicted, this drug should be administered carefully, taking such measures as starting with a lower dose (3) Patients with renal dysfunction Since renal dysfu Read the complete document